Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Amortizatization of Intangibles: 2014-2024

Historic Amortizatization of Intangibles for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $13.5 million.

  • Syndax Pharmaceuticals' Amortizatization of Intangibles fell 21.09% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year decrease of 13.04%. This contributed to the annual value of $13.5 million for FY2024, which is 9.02% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Amortizatization of Intangibles of $13.5 million as of FY2024, which was down 9.02% from $14.8 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Amortizatization of Intangibles peaked at $14.8 million during FY2023, and registered a low of -$644,000 during FY2021.
  • In the last 3 years, Syndax Pharmaceuticals' Amortizatization of Intangibles had a median value of $13.5 million in 2024 and averaged $10.6 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first plummeted by 595.38% in 2021, then soared by 625.16% in 2022.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Amortizatization of Intangibles stood at $130,000 in 2020, then tumbled by 595.38% to -$644,000 in 2021, then soared by 625.16% to $3.4 million in 2022, then surged by 337.70% to $14.8 million in 2023, then dropped by 9.02% to $13.5 million in 2024.